NIH Confirms Safety Of 2 Experimental Ebola Vaccines

Reuters: Two experimental Ebola vaccines pass safety test in African trial
“Two experimental Ebola vaccines, one from GlaxoSmithKline PLC and the other from biotech start-up NewLink Genetics Corp, ‘appear to be safe’ part way through a clinical trial being conducted in Liberia, the U.S. National Institutes of Health (NIH) said on Thursday…” (Begley, 3/26).

Wall Street Journal: Two Experimental Ebola Vaccines Appear to Be Safe in Trial
“…The safety goals for the vaccines have been met, but proving that they are effective — the next step in the research — now appears to be a more complicated project than originally envisioned. Investigators had planned to enroll 27,000 people in Liberia at a high risk of developing Ebola, such as health care workers…” (Burton, 3/26).

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.